Lijie Xing
Overview
Explore the profile of Lijie Xing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li W, Wang Y, Xing L, Song W, Lu S
Foods
. 2025 Mar;
14(5).
PMID: 40077415
As an important crop in the world, dried pepper is widely used in various foods. However, the sensory quality, fruit shape index, edible index, nutrition index, and volatile components of...
2.
Liu D, Yin X, Wang H, Xing L, Li P, Wei H, et al.
Front Oncol
. 2025 Jan;
14():1504809.
PMID: 39834945
Objective: Patients with hematological malignancies have an elevated risk of developing pneumonia after contracting COVID-19. Lymphoma is the most prevalent hematologic malignancy. It is critical to identify patients at high...
3.
Yin X, He Q, Liu D, Xie L, Wang H, Chen C, et al.
Cancer
. 2025 Jan;
131(1):e35697.
PMID: 39748728
Background: Double-expressor lymphoma (DEL) has a poorer prognosis than other subtypes of diffuse large B-cell lymphoma (DLBCL). This study is a multicenter, prospective, single-arm, phase 2 clinical study initiated by...
4.
Yang L, Wu M, Yang H, Sun X, Xing L, Liu D, et al.
Front Immunol
. 2024 Sep;
15:1441404.
PMID: 39290703
Background: High-risk double-expressor diffuse large B-cell lymphoma has an inferior prognosis following standard first-line therapy. After failure of second-line therapy, treatment options are limited if accompanied by localized compressive symptoms....
5.
Lu K, Wang W, Liu Y, Xie C, Liu J, Xing L
Front Oncol
. 2024 Aug;
14:1413494.
PMID: 39087026
Multiple myeloma (MM) is the most prevalent malignant monoclonal disease of plasma cells. There is mounting evidence that interactions with the bone marrow (BM) niche are essential for the differentiation,...
6.
Liu J, Xing L, Li J, Wen K, Liu N, Liu Y, et al.
Nat Commun
. 2024 Feb;
15(1):1367.
PMID: 38355622
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood. Here, we identify, via two...
7.
Xing L, Liu Y, Li W, Zou L, Wang Y, Luo R
Food Chem X
. 2023 Dec;
20:100956.
PMID: 38144806
A method for the simultaneous determination of 21 triazole fungicides in animal-origin foods was established by using UPLC-MS/MS. The dilution solvent, extraction solvent, and QuEChERS purification adsorbent composition, were optimized....
8.
Xing L, Liu Y, Liu J
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190168
Multiple myeloma (MM) is an incurable cancer of the plasma cells. In the last twenty years, treatment strategies have evolved toward targeting MM cells-from the shotgun chemotherapy approach to the...
9.
Xing L, Wang H, Liu D, He Q, Li Z
Front Oncol
. 2023 Feb;
12:1079890.
PMID: 36741708
Introduction: Double-expressor diffuse large B-cell lymphoma (DEL), harboring double expression of MYC and BCL2, has an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP)....
10.
Chen H, Yu T, Lin L, Xing L, Cho S, Wen K, et al.
Blood Cancer J
. 2022 Aug;
12(8):118.
PMID: 35973981
We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs). GSIs-induced membrane BCMA (mBCMA) accumulation...